BDR Pharma gets DCGI nod for generic antibiotic drug Biapenem

Biapenem is a carbapenem used for treatment of moderate and severe bacterial infections.

Published On 2021-09-25 08:23 GMT   |   Update On 2021-09-25 08:23 GMT

New Delhi: BDR Pharmaceuticals on Friday said it has received approval from Drugs Controller General of India (DCGI) for its generic antibiotic drug Biapenem used for treatment of patients with intra-abdominal infections, lower respiratory infections, and complicated urinary tract infections.The drug from the company in the form of an injection in 300mg strength will be available in the...

Login or Register to read the full article

New Delhi: BDR Pharmaceuticals on Friday said it has received approval from Drugs Controller General of India (DCGI) for its generic antibiotic drug Biapenem used for treatment of patients with intra-abdominal infections, lower respiratory infections, and complicated urinary tract infections.

The drug from the company in the form of an injection in 300mg strength will be available in the market shortly, BDR Pharmaceuticals said in a statement as reported by PTI.

"This drug will cover a broad spectrum of almost every infection and will be a great boon to the medical fraternity and patients," BDR Pharmaceuticals, Business Development - Director Raheel Shah said.

Biapenem is a carbapenem used for treatment of moderate and severe bacterial infections.

Medical Dialogues team had earlier reported that BDR Pharmaceuticals had launched generic Cabozantinib, used for the treatment of various types of cancer.

BDR Pharma was established in 2003 by Mr Dharmesh Shah.
BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology.
Tags:    
Article Source : with agency inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News